François Cherifi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
François Cherifi has a total of 299 co-authors. Here are the top co-authors by number of shared publications:
Alison Johnson
Breast Cancer Unit, CLCC François Baclesse, Institut Normand du Sein, Caen, France
5 shared publicationsMaud Villemin
Breast Cancer Unit, CLCC François Baclesse, Institut Normand du Sein, Caen, France
4 shared publicationsAngélique Da Silva
Departments of Pharmacology and Medical Oncology, Caen-Normandy University Hospital, PICARO Cardio-Oncology Program, Normandie Univ, UNICAEN, INSERM U1086 ANTICIPE, Caen, France
3 shared publications- Anne-Laure Martin
UNICANCER, Paris, France
3 shared publications Audrey Rambeau
Medical Oncology Department, Centre Francois Baclesse, Caen, France
3 shared publicationsFlorence Joly
CHU de Caen
3 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 14
Neoadjuvant versus adjuvant chemotherapy in luminal B-like breast cancer: a subset analysis of the CANTO study
- 12 October 2026
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 14
Open AccessNeoadjuvant versus adjuvant chemotherapy in luminal B-like breast cancer: a subset analysis of the CANTO study
- Open Access
Spatially informed comprehensive tumor transcriptomic profiling stratifies clinical outcomes in early triple negative breast cancer
The intensification of neoadjuvant therapy for early triple-negative breast cancer (eTNBC) – through the addition of carboplatin to standard chemotherapy and the incorporation of pembrolizumab – has markedly improved prognosis in recent years. However, this escalation carries a substantial risk of toxicity, and not all patients require the full regimen to achieve benefit. Realizing individualized treatment strategies will therefore depend on prognostic and predictive biomarkers that can forecast treatment response and long-term outcome. In the present study, we interrogated public gene expression datasets to develop transcriptomic signatures predicting response to neoadjuvant treatment and risk of recurrence. To validate these signatures, we used the Multiplex8+ platform for spatially informed comprehensive transcriptomic profiling in a real-world, multicenter, retrospective cohort of 590 patients diagnosed with eTNBC and treated with neoadjuvant chemotherapy with or without immunotherapy. The diagnostic Multiplex8+ test uses H&E and multiplexed RNA-FISH to guide the selection of specific tumor areas for the whole transcriptome sequencing and signature analysis. In the real-world cohort, the Multiplex8+ signatures were associated with both response and prognosis, remaining highly significant in multivariable models that included clinical parameters. The signatures were complementary to established biomarkers such as stromal tumor-infiltrating lymphocytes. These findings warrant prospective integration of the signatures into risk-stratified clinical trials to support future de-escalation and escalation strategies, enabling a better balance of efficacy, toxicity, cost, and drug availability.
Open AccessSpatially informed comprehensive tumor transcriptomic profiling stratifies clinical outcomes in early triple negative breast cancer
The intensification of neoadjuvant therapy for early triple-negative breast cancer (eTNBC) – through the addition of carboplatin to standard chemotherapy and the incorporation of pembrolizumab – has markedly improved prognosis in recent years. However, this escalation carries a substantial risk of toxicity, and not all patients require the full regimen to achieve benefit. Realizing individualized treatment strategies will therefore depend on prognostic and predictive biomarkers that can forecast treatment response and long-term outcome. In the present study, we interrogated public gene expression datasets to develop transcriptomic signatures predicting response to neoadjuvant treatment and risk of recurrence. To validate these signatures, we used the Multiplex8+ platform for spatially informed comprehensive transcriptomic profiling in a real-world, multicenter, retrospective cohort of 590 patients diagnosed with eTNBC and treated with neoadjuvant chemotherapy with or without immunotherapy. The diagnostic Multiplex8+ test uses H&E and multiplexed RNA-FISH to guide the selection of specific tumor areas for the whole transcriptome sequencing and signature analysis. In the real-world cohort, the Multiplex8+ signatures were associated with both response and prognosis, remaining highly significant in multivariable models that included clinical parameters. The signatures were complementary to established biomarkers such as stromal tumor-infiltrating lymphocytes. These findings warrant prospective integration of the signatures into risk-stratified clinical trials to support future de-escalation and escalation strategies, enabling a better balance of efficacy, toxicity, cost, and drug availability.
- Open Access
- 5 June 2026
- Published by Wiley in British Journal of Pharmacology
Ischaemic stroke and 5‐fluorouracil or capecitabine: A systematic review and meta‐analysis of harms and a retrospective study of the WHO pharmacovigilance database
Aim: Fluoropyrimidines, including 5‐fluorouracil (5‐FU) and capecitabine, are cornerstone antineoplastic agents for cancer. Case reports suggest that these drugs may be associated with an under‐recognised risk of ischaemic stroke or transient ischaemic attack (TIA). Methods: A systematic search of MEDLINE, Cochrane Library and ClinicalTrial.gov was conducted, using terms related to 5‐FU/capecitabine and ischaemic stroke or TIA (PROSPERO registration number CRD42024576733). An additional bibliographic survey of eligible studies was carried out for adverse events (AEs). Randomised clinical trials (RCTs) were included if they reported at least one case of ischaemic stroke or TIA events in adult cancer patients treated with 5‐FU/capecitabine. Data extraction and quality assessment followed PRISMA guidelines. Pooled Peto's odds‐ratios (Peto OR) were calculated with random effects models. Results: 13,115 patients from 23 RCTs were included, with 67 ischaemic strokes or TIAs reported. Treatment with 5‐FU/capecitabine was associated with a significantly increased risk of ischaemic stroke or TIA (Peto OR = 2.1; 95% CI [1.3–3.4]; P = 0.003; I 2 = 0%; χ 2 = 0.81). The association was similar for ischaemic stroke only (60 events; Peto OR = 2.2; 95% CI [1.3–3.4]; P = 0.001; I 2 = 0%; χ 2 = 0.83) and remained significant in RCTs using only 5‐FU (10 RCTs; various cancer sites; Peto OR = 3.1; 95% CI [1.2–7.8]; P = 0.017; I 2 = 0%; χ 2 = 0.83). Conclusion: 5‐FU/capecitabine treatment was associated with an increased risk of ischaemic stroke or TIA. Clinicians should be aware of this rare, but serious, AE.
- 5 June 2026
- Published by Wiley in British Journal of Pharmacology
Open AccessIschaemic stroke and 5‐fluorouracil or capecitabine: A systematic review and meta‐analysis of harms and a retrospective study of the WHO pharmacovigilance database
Aim: Fluoropyrimidines, including 5‐fluorouracil (5‐FU) and capecitabine, are cornerstone antineoplastic agents for cancer. Case reports suggest that these drugs may be associated with an under‐recognised risk of ischaemic stroke or transient ischaemic attack (TIA). Methods: A systematic search of MEDLINE, Cochrane Library and ClinicalTrial.gov was conducted, using terms related to 5‐FU/capecitabine and ischaemic stroke or TIA (PROSPERO registration number CRD42024576733). An additional bibliographic survey of eligible studies was carried out for adverse events (AEs). Randomised clinical trials (RCTs) were included if they reported at least one case of ischaemic stroke or TIA events in adult cancer patients treated with 5‐FU/capecitabine. Data extraction and quality assessment followed PRISMA guidelines. Pooled Peto's odds‐ratios (Peto OR) were calculated with random effects models. Results: 13,115 patients from 23 RCTs were included, with 67 ischaemic strokes or TIAs reported. Treatment with 5‐FU/capecitabine was associated with a significantly increased risk of ischaemic stroke or TIA (Peto OR = 2.1; 95% CI [1.3–3.4]; P = 0.003; I 2 = 0%; χ 2 = 0.81). The association was similar for ischaemic stroke only (60 events; Peto OR = 2.2; 95% CI [1.3–3.4]; P = 0.001; I 2 = 0%; χ 2 = 0.83) and remained significant in RCTs using only 5‐FU (10 RCTs; various cancer sites; Peto OR = 3.1; 95% CI [1.2–7.8]; P = 0.017; I 2 = 0%; χ 2 = 0.83). Conclusion: 5‐FU/capecitabine treatment was associated with an increased risk of ischaemic stroke or TIA. Clinicians should be aware of this rare, but serious, AE.
- Open Access
- 25 May 2026
- Published by Elsevier in SSRN Electronic Journal
Impact of sociality on the circumstances of breast cancer diagnosis
Background: Sociality, including networks and support, influences health outcomes. In breast cancer, socio-economic factors affect screening uptake, but the impact of social isolation and networks on diagnosis pathways remains understudied. This study examines how sociality shapes breast cancer diagnosis circumstances using data from a large national French cohort. Methods: We analyzed 7,316 women aged 50–74 with localized breast cancer from the French CANTO cohort. Sociality was assessed via questionnaire items on relationships, support, and activities. Diagnosis circumstances were classified as screening or clinical examination. Logistic regression models assessed associations, adjusting for clinical, demographic, and socio-economic factors. Internal consistency and construct validity were also evaluated. Results: Women diagnosed by screening (n=5,313) were older, had less advanced disease, higher education and income, and participated more in cultural, social, and religious activities than those diagnosed clinically (n=2,003). After full adjustment, participation in religious/spiritual activities remained the only sociality-related factor significantly associated with diagnosis modality. Higher age, lower comorbidity index and higher income were strongly associated with diagnosis through screening. The items measuring socialty showed low internal consistency; factor analysis identified four sociality dimensions explaining 33% of variance. Conclusions: Clinical factors strongly influence breast cancer diagnosis circumstances. Certain socio-economic and sociality factors, particularly income and religious/spiritual engagement, also shape diagnostic pathways. Weak associations with broader sociality may reflect measurement limitations. Developing precise, context-specific sociality tools could help identify vulnerable women and guide interventions to improve screening uptake and reduce diagnostic disparities.
- 25 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessImpact of sociality on the circumstances of breast cancer diagnosis
Background: Sociality, including networks and support, influences health outcomes. In breast cancer, socio-economic factors affect screening uptake, but the impact of social isolation and networks on diagnosis pathways remains understudied. This study examines how sociality shapes breast cancer diagnosis circumstances using data from a large national French cohort. Methods: We analyzed 7,316 women aged 50–74 with localized breast cancer from the French CANTO cohort. Sociality was assessed via questionnaire items on relationships, support, and activities. Diagnosis circumstances were classified as screening or clinical examination. Logistic regression models assessed associations, adjusting for clinical, demographic, and socio-economic factors. Internal consistency and construct validity were also evaluated. Results: Women diagnosed by screening (n=5,313) were older, had less advanced disease, higher education and income, and participated more in cultural, social, and religious activities than those diagnosed clinically (n=2,003). After full adjustment, participation in religious/spiritual activities remained the only sociality-related factor significantly associated with diagnosis modality. Higher age, lower comorbidity index and higher income were strongly associated with diagnosis through screening. The items measuring socialty showed low internal consistency; factor analysis identified four sociality dimensions explaining 33% of variance. Conclusions: Clinical factors strongly influence breast cancer diagnosis circumstances. Certain socio-economic and sociality factors, particularly income and religious/spiritual engagement, also shape diagnostic pathways. Weak associations with broader sociality may reflect measurement limitations. Developing precise, context-specific sociality tools could help identify vulnerable women and guide interventions to improve screening uptake and reduce diagnostic disparities.
- Open Access
- 22 May 2026
- Published by Elsevier in The Breast
- Vol. 88, 104816
Characteristics, treatment and survival of older patients with metastatic triple negative breast cancer from the ESME mBC real-world national cohort: a comparison with younger women
- 22 May 2026
- Published by Elsevier in The Breast
- Vol. 88, 104816
Open AccessCharacteristics, treatment and survival of older patients with metastatic triple negative breast cancer from the ESME mBC real-world national cohort: a comparison with younger women
- Open Access
- 26 March 2026
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 145, 103121
Hematological immune-related adverse events associated with checkpoint inhibitors
- 26 March 2026
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 145, 103121
Open AccessHematological immune-related adverse events associated with checkpoint inhibitors
- Open Access
- 11 December 2025
- Published by Elsevier in Clinical Surgical Oncology
- Vol. 4 (4)
Metastatic sites and surgical management in stage IV ovarian cancer: Is there a place for debulking surgery in FIGO stage IVB patients? A retrospective study from the ESME national cohort
- 11 December 2025
- Published by Elsevier in Clinical Surgical Oncology
- Vol. 4 (4)
Open AccessMetastatic sites and surgical management in stage IV ovarian cancer: Is there a place for debulking surgery in FIGO stage IVB patients? A retrospective study from the ESME national cohort
- Open Access
PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohort
- Open Access
- 5 October 2025
- Published by Springer Nature in Research Square
Pembrolizumab in patients with rare ovarian cancers : analysis from AcSé Pembrolizumab phase II multicentric basket trial
Rare ovarian cancer is a heterogeneous group of diseases with significant unmet medical needs and low chemotherapy sensitivity. In this context, the AcSé Pembrolizumab (NCT03012620) multicentric, non-randomized, phase II basket trial, assessing pembrolizumab monotherapy in rare tumors has been conducted. We report here the results from the rare ovarian cancer cohort. Primary outcome was the objective response rate (ORR) at week 12. Secondary endpoints included best ORR, clinical benefit rate, survival and safety. ORR at week 12 was 3.2% (95%CI, 0.4% to 11.2%), with one partial (PR) and one complete response (CR) in a patient with a teratoma with malignant transformation remaining in CR six years after initiating pembrolizumab. Stable disease (SD) was observed in 34% of patients, including one patient with carcinosarcoma maintaining a SD for 33 months. No new safety concerns and no deaths related to pembrolizumab were observed. Pembrolizumab in rare ovarian tumor subtypes showed limited ORR but promising long-term benefit in selected patients were observed.
- 5 October 2025
- Published by Springer Nature in Research Square
Open AccessPembrolizumab in patients with rare ovarian cancers : analysis from AcSé Pembrolizumab phase II multicentric basket trial
Rare ovarian cancer is a heterogeneous group of diseases with significant unmet medical needs and low chemotherapy sensitivity. In this context, the AcSé Pembrolizumab (NCT03012620) multicentric, non-randomized, phase II basket trial, assessing pembrolizumab monotherapy in rare tumors has been conducted. We report here the results from the rare ovarian cancer cohort. Primary outcome was the objective response rate (ORR) at week 12. Secondary endpoints included best ORR, clinical benefit rate, survival and safety. ORR at week 12 was 3.2% (95%CI, 0.4% to 11.2%), with one partial (PR) and one complete response (CR) in a patient with a teratoma with malignant transformation remaining in CR six years after initiating pembrolizumab. Stable disease (SD) was observed in 34% of patients, including one patient with carcinosarcoma maintaining a SD for 33 months. No new safety concerns and no deaths related to pembrolizumab were observed. Pembrolizumab in rare ovarian tumor subtypes showed limited ORR but promising long-term benefit in selected patients were observed.